Literature DB >> 19478676

Nonalcoholic fatty liver disease/nonalcoholic steatohepatitis: histological diagnostic criteria and scoring systems.

Dina G Tiniakos1.   

Abstract

Nonalcoholic fatty liver disease (NAFLD) is recognized as the most common cause of chronic liver disease in western countries. NAFLD is etiologically associated with systemic and hepatic insulin resistance and is considered by many as the hepatic manifestation of the metabolic syndrome. NAFLD has a wide histological spectrum ranging from 'simple' steatosis to nonalcoholic steatohepatitis (NASH), which may progress to cirrhosis. Hepatocellular carcinoma may occur in NASH-related cirrhosis. The diagnosis of NAFLD/NASH is based on clinico-pathological criteria. Currently available noninvasive tests for the diagnosis of NASH lack specificity and sensitivity, so liver biopsy, despite its limitations, still remains the 'golden standard' for confirming or excluding NASH in a patient with chronically-elevated liver enzymes and image-detected steatosis. This review examines the currently used criteria for the histopathological diagnosis of NAFLD/NASH in adults and children and the relevant histological scoring systems.

Entities:  

Mesh:

Year:  2010        PMID: 19478676     DOI: 10.1097/MEG.0b013e32832ca0cb

Source DB:  PubMed          Journal:  Eur J Gastroenterol Hepatol        ISSN: 0954-691X            Impact factor:   2.566


  26 in total

Review 1.  Histopathology of nonalcoholic fatty liver disease.

Authors:  Elizabeth M Brunt; Dina G Tiniakos
Journal:  World J Gastroenterol       Date:  2010-11-14       Impact factor: 5.742

Review 2.  What is the role of adiponectin in obesity related non-alcoholic fatty liver disease?

Authors:  Carmine Finelli; Giovanni Tarantino
Journal:  World J Gastroenterol       Date:  2013-02-14       Impact factor: 5.742

3.  Protective effect of probucol on liver injury induced by carbon tetrachloride in rats.

Authors:  Yu-Tao Zhan; Jing Weng; Li Li; Qing Xu; Xin Song; Xiao-Xia Guo
Journal:  Hepatol Int       Date:  2011-02-10       Impact factor: 6.047

4.  Role of ezetimibe in non-alcoholic fatty liver disease.

Authors:  Theodosios D Filippatos; Moses S Elisaf
Journal:  World J Hepatol       Date:  2011-10-27

Review 5.  Histopathology of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.

Authors:  Yoshihisa Takahashi; Toshio Fukusato
Journal:  World J Gastroenterol       Date:  2014-11-14       Impact factor: 5.742

Review 6.  Therapeutic opportunities for alcoholic steatohepatitis and nonalcoholic steatohepatitis: exploiting similarities and differences in pathogenesis.

Authors:  Thomas Greuter; Harmeet Malhi; Gregory J Gores; Vijay H Shah
Journal:  JCI Insight       Date:  2017-09-07

Review 7.  Histological Assessment of NAFLD.

Authors:  Pierre Bedossa
Journal:  Dig Dis Sci       Date:  2016-02-13       Impact factor: 3.199

8.  Combination drug treatment in patients with non-alcoholic fatty liver disease.

Authors:  Theodosios D Filippatos; Moses S Elisaf
Journal:  World J Hepatol       Date:  2010-04-27

Review 9.  The role of hepatic fat accumulation in pathogenesis of non-alcoholic fatty liver disease (NAFLD).

Authors:  Qing Liu; Stig Bengmark; Shen Qu
Journal:  Lipids Health Dis       Date:  2010-04-28       Impact factor: 3.876

Review 10.  MRI and MRE for non-invasive quantitative assessment of hepatic steatosis and fibrosis in NAFLD and NASH: Clinical trials to clinical practice.

Authors:  Parambir S Dulai; Claude B Sirlin; Rohit Loomba
Journal:  J Hepatol       Date:  2016-06-14       Impact factor: 25.083

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.